pepmg_
TRI-BLENDnamed blend

Blend dossier · component evidence, sources, and live market

TRI-BLEND

3-compound blend blend evidence is component-scoped 6 cited studies 3 live vendors

A vendor-sold three-compound repair blend. This page treats TRI-BLEND as a market product while keeping research claims attached to the individual ingredients actually studied.

Common market formula

BPC-157 / TB-500 / KPV. Vendor formulations can vary; each vendor's published product description controls.

BPC-157TB-500KPV

cheapest total
$99.99
highest total
$129.00
first-party vendors
3
vendors publishing COAs
3
Fair-price band · 3 first-party vendors · total product price
median $129.00
$99.99cheapest$129.00highest
Comparing vendors can save up to $29.01 per product. Blends are ranked by total price, never by a mixed-peptide $/mg figure.

Vendor links are temporarily offline while we review our referral and linking policies. Listings remain for price transparency.

first-party prices captured 8m ago

email only when a vendor actually lowers this blend's total product price · one-click stop
TRI-BLEND · first-party live pricessorted by total · 3 listings
#VendorPublished product / formulaCOATotal
1Nextech Laboratories TRI BLEND (BPC-157/TB500/KPV) (10mg/10mg/10mg)BLENDcaptured 6m ago 2 at lab $99.99
2Atomik Labz TRI-BLEND (BPC-157/TB-500/KPV) 10mg 10mg 10mgBLENDcaptured 7m ago publishes $129.00
3Solution Peptides TRI-BLEND (BPC-157 / TB-500 / KPV) 10mg 10mg 10mgBLENDcaptured 5m ago publishes $129.00
COA availability: 3 of 3 sources selling TRI-BLEND publish a COA — 1 with at least one certificate openable at the testing lab. This is vendor-level evidence, not proof that a particular certificate covers the exact blend/formula row. What a COA proves →
Component research relevant to TRI-BLENDclaims stay attached to ingredients
Peer-reviewed component research · TRI-BLENDsource: PubMed
  1. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing PubMed ↗
    BPC-157Review2019 · PMID 30915550

    There is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and recurring musculoskeletal soft tissue injuries and disorders. Currently, several therapies are emerging an…

  2. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing PubMed ↗
    BPC-157Review2021 · PMID 34267654

    Significance: The antiulcer peptide, stable gastric pentadecapeptide BPC 157 (previously employed in ulcerative colitis and multiple sclerosis trials, no reported toxicity (LD1 not achieved)), is reviewed, focusing on the particular skin…

  3. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review PubMed ↗
    BPC-157Review2025 · PMID 40756949

    Background: Body protection compound-157 (BPC-157) is a naturally occurring gastric peptide that promotes mucosal integrity and homeostasis. Preclinical studies show its potential for promoting healing in musculoskeletal injuries such as…

  4. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies PubMed ↗
    TB-500Review2023 · PMID 36709593

    Our dream of defeating the processes of organ damage and aging remains a challenge scientists pursued for hundreds of years. Although the goal is to successfully treat the body as a whole, steps towards regenerating individual organs are…

  5. Cardioprotection by Thymosin Beta 4 PubMed ↗
    TB-500Review2016 · PMID 27450736

    Treatment with thymosin beta 4 (Tβ4) reduces infarct volume and preserves cardiac function in preclinical models of cardiac ischemic injury. These effects stem in part from decreased infarct size, but additional benefits are likely due t…

  6. Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids PubMed ↗
    TB-500Study2025 · PMID 40816274

    The developmental origin of Alzheimer disease (AD) has been proposed but is arguably debated. Here, we developed cerebral organoids from induced pluripotent stem cells (iPSCs) with mutations in amyloid precursor protein (APP) associated …

These studies concern individual components, not the named blend as a finished intervention. They do not establish that combining the ingredients reproduces any result.

Ingredients in the common TRI-BLEND formulaopen each full compound dossier
All products listed are sold by third-party vendors for laboratory and research use only (RUO). Where an FDA label or a peer-reviewed study has published a dose, pepmg reports it with the source named, because that is safer than guessing. It is a report, not medical advice and not a recommendation to use anything. pepmg sells nothing and ships nothing. Listings are price-tracking data, not endorsements. pepmg describes vendor-sold blends; it does not recommend combining compounds or infer blend-level efficacy from component studies.